Scalable biomimetic SARS-CoV‑2 nanovaccines with robust protective immune responses

Signal Transduct Target Ther. 2022 Mar 25;7(1):96. doi: 10.1038/s41392-022-00942-y.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomimetics
  • COVID-19*
  • Humans
  • Immunity
  • SARS-CoV-2*
  • Viral Envelope Proteins

Substances

  • Viral Envelope Proteins